LUND, Sweden, Aug. 22, 2019 /PRNewswire/ -- Cantargia AB's ("Cantargia") half year report for the period January until June 2019 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.
Significant events in the second quarter
In May 2019, Cantargia AB and Patheon Biologics B.V. (a part of ThermoFischer Scientific) signed an agreement on future production of the CAN04 antibody.
In May 2019, Cantargia announced new preclinical results showing positive effects when the CAN04 antibody is combined with various platinum-based chemotherapies.
New phase I clinical data on Cantargia´s antibody CAN04 (nidanilimab) were presented June 2 in an oral session at the 2019 ASCO Annual Meeting.
Significant events after the end of the period
Cantargia announced in July full recruitment of CAN04 monotherapy arm in the ongoing phase IIa clinical trial.
Financial information
First half (1 Jan 2019 ? 30 Jun 2019)
Net sales, kSEK 0 (0)
Operating loss, kSEK -48,857 (-43,812)
Loss after tax, kSEK -48,533 (-41,846)
Loss per share, before and after dilution, SEK -0.70 (-0.63)
Equity/assets ratio, 91 (93) per cent
Cash and cash equivalents, kSEK 59,174 (102,786)
Short-term investments, kSEK 160,019 (110,000)
Second quarter 2019 (1 Apr 2019 ? 30 Jun 2019)
Net sales, kSEK 0 (0)
Operating loss, kSEK -25,196 (-28,563)
Loss after tax, kSEK -25,012 (-28,147
Earnings per share, before and after dilution, SEK -0.34 (-0.43)
This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on August 22, 2019.
About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04 (nidanilimab) is being studied in the clinical phase I/IIa CANFOUR with a primary focus on non-small cell lung cancer and pancreatic cancer. The study is conducting both monotherapy and combination therapy. Cantargia's other project, CANxx, is in the research phase and is aiming to develop an IL1RAP binding antibody optimised for the treatment of autoimmune and inflammatory diseases.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at http://www.cantargia.com.
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference.
On April 26, 2024, the hearing will commence 11:15 a.m.
Members of the public may observe the hearing by videoconference, by...
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...
DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market...
Enghouse Video, a global leader in cutting-edge video technology solutions, today announced its partnership with SONIFI Health, enhancing virtual care in hospital settings.
SONIFI Health is a leading U.S. healthcare technology company based in Sioux...
A record 3,618 graduating students and physicians matched to residency training programs in Canada in this year's R-1 Main Residency Match (R-1 match), the Canadian Resident Matching Service (CaRMS) announced today....